MAP2K7 and melanoma: MEK inhibitors have been evaluated in dozens of clinical trials as monotherapy and in combination with other agents, and to-date, have only been approved for use in combination with BRAF inhibitors in BRAF mutant melanoma (clinicaltrials.gov).